利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.02 秒)

    HYPO-IMMUNOGENIC STREPTAVIDIN AND USE THEREOF
    4.
    发明公开
    HYPO-IMMUNOGENIC STREPTAVIDIN AND USE THEREOF 有权
    HYPO-IMMUNOGENES STREPTAVIDIN UNDER VENWENDUNG

    公开(公告)号：EP2399993A1

    公开(公告)日：2011-12-28

    申请号：EP10743584.4

    申请日：2010-02-19

    申请人： The University of Tokyo ,  Perseus Proteomics Inc.

    发明人： KODAMA, Tatsuhiko ,  HAMAKUBO, Takao ,  DOI, Hirofumi ,  SUGIYAMA, Akira ,  TSUMOTO, Kouhei

    IPC分类号： C12N15/09 ,  A61K31/4188 ,  A61K38/00 ,  A61K39/395 ,  A61P37/06 ,  C07K14/195 ,  C07K16/00 ,  C07K19/00 ,  G01N33/53

    CPC分类号： B82Y5/00 ,  A61K47/6898 ,  C07K14/36 ,  C07K16/14 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/92

    摘要： It is an object of the present invention to provide a mutant streptavidin wherein the immunogenicity (antigenicity) in mammals of a streptavidin is reduced. The present invention provides a mutant streptavidin, which comprises an amino acid sequence in which (a) the arginine residue at position 72 is substituted with another amino acid residue, and (b) any one or more of the tyrosine residue at position 10, the tyrosine residue at position 71, the glutamic acid residue at position 89, the arginine residue at position 91, and the glutamic acid residue at position 104 are substituted with other amino acid residues, with respect to the amino acid sequence of a core streptavidin as shown in SEQ ID NO: 2, and which has decreased immunogenicity as compared with that of a wild-type streptavidin.

    摘要翻译： 本发明的一个目的是提供一种突变链霉抗生物素蛋白，其中链霉抗生物素蛋白的哺乳动物中的免疫原性（抗原性）降低。 本发明提供一种突变链霉抗生物素蛋白，其包含其中（a）第72位的精氨酸残基被另一个氨基酸残基取代的氨基酸序列，和（b）第10位的任何一个或多个酪氨酸残基， 对于核心链霉抗生物素蛋白的氨基酸序列，如图所示，第71位的酪氨酸残基，89位的谷氨酸残基，91位的精氨酸残基和104位的谷氨酸残基被其他氨基酸残基取代 与野生型链霉抗生物素蛋白相比具有降低的免疫原性。

    AGENT FOR TREATING OR PREVENTING SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
    10.
    发明公开
    AGENT FOR TREATING OR PREVENTING SYSTEMIC INFLAMMATORY RESPONSE SYNDROME 审中-公开
    MITTEL ZUR BEHANDLUNG ODER VORBEUGUNG VON SYSTEMISCHEMENTZÜNDUNGSREAKTIONSSYNDROM

    公开(公告)号：EP2865384A1

    公开(公告)日：2015-04-29

    申请号：EP13807573.4

    申请日：2013-06-21

    申请人： The University of Tokyo

    发明人： HAMAKUBO, Takao ,  TSUMOTO, Kouhei ,  DAIGO, Kenji ,  INOUE, Kenji ,  YAMAGUCHI, Naotaka ,  MIZUUCHI, Motoaki ,  FUJII, Hiroya

    IPC分类号： A61K38/00 ,  A61P29/00 ,  C07K14/435 ,  C12P21/02 ,  C12N15/09

    CPC分类号： C07K14/47 ,  A61K38/00 ,  G01N33/6875

    摘要： The present invention provides a therapeutic or prophylactic agent for systemic inflammatory response syndrome (SIRS), which contains a polypeptide comprising an amino acid sequence the same or substantially the same as the amino acid sequence of the N-terminal domain of pentraxin 3 capable of binding to histone to form a polypeptide aggregate, or a pharmacologically acceptable salt thereof. The present invention also provides a reagent for quantification and a quantification method of histone, which utilize the polypeptide or a pharmacologically acceptable salt thereof. Furthermore, the present invention provides a polypeptide aggregate containing the polypeptide or a pharmacologically acceptable salt thereof and histone and a production method thereof.

    摘要翻译： 本发明提供了一种全身炎症反应综合征（SIRS）的治疗或预防剂，其包含多肽，该多肽包含与能够结合的pentraxin 3的N-末端结构域的氨基酸序列相同或基本相同的氨基酸序列 组蛋白以形成多肽骨架或其药理学上可接受的盐。 本发明还提供一种组蛋白的定量试剂和定量方法，该方法利用多肽或其药理学上可接受的盐。 此外，本发明提供含有多肽或其药理学上可接受的盐和组蛋白的多肽骨架及其制备方法。